Literature DB >> 15504881

In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.

Giovanni Di Bonaventura1, Ilaria Spedicato, Carla Picciani, Domenico D'Antonio, Raffaele Piccolomini.   

Abstract

Time-kill and postantifungal effect (PAFE) of amphotericin B, caspofungin, fluconazole, and voriconazole were determined against clinical isolates of Candida guilliermondii, Candida kefyr, and Candida lusitaniae. Azoles displayed fungistatic activity and no measurable PAFE, regardless of the concentration tested. Amphotericin B and caspofungin demonstrated concentration-dependent fungicidal activity, although amphotericin B only produced a significant dose-dependent PAFE against all isolates tested.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15504881      PMCID： PMC525414          DOI： 10.1128/AAC.48.11.4453-4456.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

Authors:  S Schwartz; D Milatovic; E Thiel
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

2.  Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii.

Authors:  J D Dick; B R Rosengard; W G Merz; R K Stuart; G M Hutchins; R Saral
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

Review 3.  Mycoses caused by Candida lusitaniae.

Authors:  T L Hadfield; M B Smith; R E Winn; M G Rinaldi; C Guerra
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

4.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 5.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

Review 6.  New and emerging yeast pathogens.

Authors:  K C Hazen
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Organism-dependent fungicidal activities of azoles.

Authors:  E K Manavathu; J L Cutright; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-02       Impact factor: 2.803

9.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.

Authors:  Anne Favel; Annie Michel-Nguyen; Annick Datry; Svetlana Challier; Florence Leclerc; Christiane Chastin; Karim Fallague; Patrick Regli
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790
View more
  15 in total

1.  Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Serena Tomassetti; Agnese Della Vittoria; Daniela Arzeni; Esther Manso; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.

Authors:  Cornelius J Clancy; Hong Huang; Shaoji Cheng; Hartmut Derendorf; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.

Authors:  Pedro Póvoa; João Gonçalves-Pereira
Journal:  Crit Care       Date:  2011-01-31       Impact factor: 9.097

4.  Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.

Authors:  Yasemin Oz; Ilknur Dag; Nuri Kiraz
Journal:  Mycopathologia       Date:  2011-08-13       Impact factor: 2.574

Review 6.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.

Authors:  Gulsen Hazirolan; Emilia Canton; Selma Sahin; Sevtap Arikan-Akdagli
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

Review 9.  Pharmacological properties of antifungal drugs with a focus on anidulafungin.

Authors:  Teresita Mazzei; Andrea Novelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.

Authors:  Yanjun Li; M Hong Nguyen; Hartmut Derendorf; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.